Results 161 to 170 of about 1,702,455 (203)
Thrombopoietin-Receptor Agonists for Primary Immune Thrombocytopenia
New England Journal of Medicine, 2011 A 26-year-old woman with a history of chronic primary immune thrombocytopenia presents for evaluation. Her condition was first diagnosed when she was 11 years of age. Her platelet count has typically been less than 10,000 per cubic millimeter. Her symptoms have not responded to glucocorticoids, and she has had only transient responses to intravenous ...
Mark Crowther, Paul Imbach
exaly +4 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Thrombopoietin-receptor agonists
Current Opinion in Hematology, 2012Thrombopoietin-receptor agonists (TPO-RAs) have been approved for use in immune thrombocytopenia (ITP) after showing safety and efficacy. There is increasing interest to expand the role of TPO-RAs, both in ITP as well as in other thrombocytopenic disorders.In ITP, more studies are providing evidence of TPO-RA efficacy and safety, as well as their ...
Paul A, Basciano, James B, Bussel
openaire +2 more sources
Hemostatic Changes by Thrombopoietin-Receptor Agonists in Immune Thrombocytopenia Patients [PDF]
Blood Reviews, 2021 Thrombopoietin receptor agonist (TPO-RA) treatment increases the thrombosis rate in immune thrombocytopenia (ITP). We hypothesize that TPO-RAs influence platelet function, global and secondary hemostasis and/or fibrinolysis.
Wobke E M van Dijk +2 more
exaly +1 more source
Thrombopoietin Receptor Agonists: A New Immune Modulatory Strategy in Immune Thrombocytopenia?
Seminars in Hematology, 2016 In 2008, new drugs that mimic the effects of thrombopoietin became available for the treatment of primary immune thrombocytopenia, eg, romiplostim and eltrombopag.
Alexandra Schifferli, Thomas Kühne
exaly +2 more sources
Thrombopoietin Receptor Agonists: A Critical Review
Seminars in Hematology, 2015Thrombopoietic agents have created a paradigm shift in the management of chronic or poorly responsive immune thrombocytopenia (ITP). There are ample randomized, placebo-controlled trial data, as well as long-term data gathered for more than 5 years; short-term efficacy and safety are well documented and long-term efficacy and safety data are emerging ...
William B, Mitchell, James B, Bussel
openaire +2 more sources
Optimal Use of Thrombopoietin Receptor Agonists in Immune Thrombocytopenia [PDF]
Therapeutic Advances in Hematology, 2019 The thrombopoietin receptor agonists (TPO-RAs) are a class of platelet growth factors commonly used to treat immune thrombocytopenia (ITP). There are three agents that have been investigated for the treatment of chronic ITP: the peptide agent romiplostim and the small molecule agents eltrombopag and avatrombopag.
Hanny Al-Samkari, David John Kuter
exaly +4 more sources
The Pharmacology and Clinical Application of Thrombopoietin Receptor Agonists
International Journal of Hematology, 2014The discovery and application of thrombopoietin (TPO) and thrombopoietin receptor (TPOR) agonists have changed the clinical treatment of thrombocytopenia. These compounds exert favorable clinical effects without the adverse events caused by traditional treatments (e.g., corticosteroids, immunoglobulins, monoclonal antibodies and splenectomy).
Caizheng, Li, Li, Zheng
exaly +3 more sources
Eltrombopag: A Novel Oral Thrombopoietin Receptor Agonist
Annals of Pharmacotherapy, 2010To review the pharmacology and pharmacokinetics and evaluate the safety and efficacy of eltrombopag for the treatment of chronic immune (idiopathic) thrombocytopenic purpura (ITP) and thrombocytopenia associated with hepatitis C virus (HCV) cirrhosis.A Cochrane Controlled Trial Register, clinicaltrials.gov, EMBASE, and MEDLINE search was performed ...
Shelby L, Corman, Rima A, Mohammad
openaire +2 more sources
Thrombopoietin receptor agonists in the treatment of thrombocytopenia
Current Opinion in Hematology, 2009The basis of treatment for immune thrombocytopenic purpura (ITP) has conventionally relied on nonspecific immune suppression designed to reduce platelet destruction. As a consequence, at least half of the morbidity and mortality in this condition is related to infection secondary to treatment, and alternative treatments are desirable.It has been shown ...
openaire +2 more sources
New thrombopoietin receptor agonists for platelet disorders
Drugs of Today, 2012Since thrombopoietin (TPO) was cloned in 1994, TPO receptor (TPO-R) agonists have been developed which have shown significant clinical activity in various conditions characterized by thrombocytopenia. First-generation TPO-R agonists were recombinant forms of human TPO.
S, Homeida +7 more
openaire +2 more sources